Biohaven downgraded by RBC Capital Mkts with a new price target
$BHVN
Biotechnology: Pharmaceutical Preparations
Health Care
RBC Capital Mkts downgraded Biohaven from Outperform to Sector Perform and set a new price target of $21.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/19/2025 | $21.00 | Outperform → Sector Perform | RBC Capital Mkts |
| 2/11/2025 | $65.00 | Buy | Deutsche Bank |
| 9/16/2024 | $57.00 | Buy | Jefferies |
| 9/4/2024 | $55.00 | Outperform | Bernstein |
| 7/24/2024 | $58.00 | Overweight | Morgan Stanley |
| 2/16/2024 | $62.00 | Outperform | RBC Capital Mkts |
| 2/6/2024 | $59.00 | Buy | UBS |
| 12/22/2023 | $50.00 | Buy | H.C. Wainwright |